Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.23 Million USD | -369.07% |
| 2022 | 141.08 Thousand USD | 156.93% |
| 2021 | -247.81 Thousand USD | 95.44% |
| 2020 | -5.42 Million USD | -493.21% |
| 2019 | -915.17 Thousand USD | 77.52% |
| 2018 | -4.07 Million USD | 10.24% |
| 2017 | -4.53 Million USD | -7187.07% |
| 2016 | -62.22 Thousand USD | -271.35% |
| 2015 | -16.75 Thousand USD | 58.14% |
| 2014 | -40.03 Thousand USD | -646.92% |
| 2013 | -5360.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -71.39 Thousand USD | 42.77% |
| 2024 Q1 | -124.73 Thousand USD | -155.44% |
| 2023 Q2 | -3.96 Million USD | -3129.69% |
| 2023 Q4 | -48.83 Thousand USD | 51.33% |
| 2023 Q1 | -122.81 Thousand USD | -296.22% |
| 2023 FY | -379.62 Thousand USD | -369.07% |
| 2023 Q3 | -100.32 Thousand USD | 97.47% |
| 2022 Q1 | -81.79 Thousand USD | -225.21% |
| 2022 Q4 | -30.99 Thousand USD | 75.76% |
| 2022 Q2 | 381.73 Thousand USD | 566.72% |
| 2022 FY | 141.08 Thousand USD | 156.93% |
| 2022 Q3 | -127.86 Thousand USD | -133.49% |
| 2021 Q4 | 65.32 Thousand USD | 201.16% |
| 2021 FY | -247.81 Thousand USD | 95.44% |
| 2021 Q1 | -154.94 Thousand USD | 96.9% |
| 2021 Q3 | -64.57 Thousand USD | 31.03% |
| 2021 Q2 | -93.62 Thousand USD | 39.58% |
| 2020 Q1 | -149.28 Thousand USD | -145.9% |
| 2020 Q4 | -5 Million USD | -5307.54% |
| 2020 Q3 | -92.56 Thousand USD | 49.02% |
| 2020 Q2 | -181.58 Thousand USD | -21.64% |
| 2020 FY | -5.42 Million USD | -493.21% |
| 2019 Q2 | -263.29 Thousand USD | 34.07% |
| 2019 Q4 | -60.7 Thousand USD | 68.36% |
| 2019 FY | -915.17 Thousand USD | 77.52% |
| 2019 Q3 | -191.84 Thousand USD | 27.14% |
| 2019 Q1 | -399.32 Thousand USD | 1.47% |
| 2018 Q3 | -809.38 Thousand USD | 28.8% |
| 2018 Q2 | -1.13 Million USD | 43.16% |
| 2018 Q1 | -1.99 Million USD | -11.52% |
| 2018 FY | -4.07 Million USD | 10.24% |
| 2018 Q4 | -405.28 Thousand USD | 49.93% |
| 2017 Q1 | -1.37 Million USD | -2.67% |
| 2017 Q2 | -990.2 Thousand USD | 28.12% |
| 2017 Q4 | -1.79 Million USD | -45.75% |
| 2017 Q3 | -1.23 Million USD | -24.25% |
| 2017 FY | -4.53 Million USD | -7187.07% |
| 2016 Q3 | -55.19 Thousand USD | -2929.58% |
| 2016 Q4 | -1.34 Million USD | -2330.71% |
| 2016 Q2 | -1822.00 USD | 56.94% |
| 2016 FY | -62.22 Thousand USD | -271.35% |
| 2016 Q1 | -4231.00 USD | -333.95% |
| 2015 Q1 | -3672.00 USD | -7.06% |
| 2015 FY | -16.75 Thousand USD | 58.14% |
| 2015 Q4 | -975.00 USD | 68.51% |
| 2015 Q2 | -6559.00 USD | -78.62% |
| 2015 Q3 | -3096.00 USD | 52.8% |
| 2014 FY | -40.03 Thousand USD | -646.92% |
| 2014 Q1 | -14.21 Thousand USD | -90.5% |
| 2014 Q2 | -3491.00 USD | 75.44% |
| 2014 Q3 | -14.86 Thousand USD | -325.78% |
| 2014 Q4 | -3430.00 USD | 76.92% |
| 2013 FY | -5360.00 USD | 0.0% |
| 2013 Q2 | -4305.00 USD | 0.0% |
| 2013 Q4 | -7463.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -217.382% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 15.979% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 76.251% |
| Nascent Biotech, Inc. | -2.22 Million USD | -90.074% |
| Rebus Holdings, Inc. | -664 Thousand USD | -538.315% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.178% |
| Qrons Inc. | -643.67 Thousand USD | -558.469% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -987.972% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 92.364% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -920.127% |
| Skye Bioscience, Inc. | -13.67 Million USD | 68.999% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.096% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 186.238% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1519.409% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.41% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -48.69% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -175.93% |
| Mesoblast Limited | -84.14 Million USD | 94.963% |
| Marizyme, Inc. | -34.08 Million USD | 87.566% |
| Genus plc | 6.4 Million USD | 166.225% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 143.505% |
| Pharming Group N.V. | -4.87 Million USD | 13.139% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -113.363% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -355.068% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 49.241% |
| ContraFect Corporation | -56.88 Million USD | 92.55% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 6.945% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -202.314% |
| IMV Inc. | -38.67 Million USD | 89.04% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -54.077% |
| MultiCell Technologies, Inc. | -722.81 USD | -586280.1% |
| ONE Bio Corp. | 13.68 Million USD | 130.979% |
| Accustem Sciences Inc. | -3.74 Million USD | -13.132% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.815% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -777.406% |
| Q BioMed Inc. | -3.44 Million USD | -23.009% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 219.729% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -61.308% |
| Biomind Labs Inc. | -1 Million USD | -319.81% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 92.29% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -46.089% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 36.245% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -127.338% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -14050.688% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 73.292% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -119.31% |
| GB Sciences, Inc. | -1.42 Million USD | -198.373% |
| Alpha Cognition Inc. | -9.7 Million USD | 56.33% |
| HST Global, Inc. | -140.9 Thousand USD | -2907.951% |
| CSL Limited | 3.7 Billion USD | 100.114% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -276.779% |
| Halberd Corporation | -75.05 Thousand USD | -5547.454% |
| Enzolytics Inc. | -2.14 Million USD | -97.246% |
| Agentix Corp. | -1.37 Million USD | -208.977% |
| Resverlogix Corp. | -12.74 Million USD | 66.755% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -33.777% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.003% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -305.978% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -45.179% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -168.364% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -24.477% |
| AVAX Technologies, Inc. | 6.69 Million USD | 163.327% |
| Zenith Capital Corp. | -8.94 Million USD | 52.606% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.981% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -24229.338% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -72.622% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2371.241% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -111.418% |
| Kadimastem Ltd | -3.04 Million USD | -39.41% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -330.71% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -237.453% |
| BioStem Technologies, Inc. | -7.77 Million USD | 45.514% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2235.407% |
| LadRx Corporation | -3.82 Million USD | -10.848% |
| Cell Source, Inc. | -4.32 Million USD | 2.01% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -516.99% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -516.99% |
| NovAccess Global Inc. | -2.46 Million USD | -71.821% |
| Affymax, Inc. | -15.04 Million USD | 71.83% |
| Itoco Inc. | -919.14 Thousand USD | -361.128% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -278.768% |
| Mobile Lads Corp. | -554.55 Thousand USD | -664.298% |
| CytoDyn Inc. | -18.05 Million USD | 76.529% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -16739.15% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1825.869% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -650.53% |
| SYBLEU INC | -149.18 Thousand USD | -2741.141% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -133.352% |
| International Stem Cell Corporation | -663 Thousand USD | -539.278% |
| Bioxytran, Inc. | -3.82 Million USD | -10.949% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7951.698% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -20737.827% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 88.313% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -161.954% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -476.001% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -36.24% |
| Neutra Corp. | -229.48 Thousand USD | -1746.916% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 75.834% |
| PureTech Health plc | -146.19 Million USD | 97.101% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 80.278% |
| IXICO plc | -1.43 Million USD | -194.949% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 55.343% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.52% |
| CSL Limited | 3.81 Billion USD | 100.111% |
| Cellectis S.A. | -108.85 Million USD | 96.106% |